Clinical trial
Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell…
NCT00438581 · McGill University, Other · Unknown status
Key facts
| NCT number | NCT00438581 |
|---|---|
| Title | Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma |
| Official title | Phase II Non-Randomized Study Combining Yttrium 90 Ibritumomab Tiuxetan (Zevalin) With High-Dose Chemotherapy Prior to Autologous Stem Cell Transplantation in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma |
| Acronym | Zevalin |
| Lead sponsor | McGill University, Other |
| Collaborators | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Yttrium 90 Ibritumomab Tiuxetan ( Zevalin ) |
| Enrollment | 40 |
| Start date | Mar 1, 2007 |
| First posted | Feb 22, 2007 |
| Last update posted | Feb 27, 2007 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: